title: Galanthamine treatment in Alzheimer's disease.
abstract: 18 patients who had fulfilled the NINCDS-ADRDA criteria for "possible AD" took part in a clinical study to evaluate the effect of the cholinesterase inhibitor Galanthamine, 30 mg/day. Neuropsychological und social parameters were rated. This open clinical pilot-study showed no statistic significant change in neuropsychological test-results. However after 1 year treatment 6 patients are still taking the drug. According to their care-persons there was a positive changes in competence of everyday-routine and/or in the emotional situation.
authors.affiliation: Neurology University Clinic, Vienna, Austria.
authors.forename: P
authors.initials: P
authors.lastname: Dal-Bianco
authors.forename: J
authors.initials: J
authors.lastname: Maly
authors.forename: C
authors.initials: C
authors.lastname: Wôber
authors.forename: C
authors.initials: C
authors.lastname: Lind
authors.forename: G
authors.initials: G
authors.lastname: Koch
authors.forename: J
authors.initials: J
authors.lastname: Hufgard
authors.forename: I
authors.initials: I
authors.lastname: Marschall
authors.forename: M
authors.initials: M
authors.lastname: Mraz
authors.forename: L
authors.initials: L
authors.lastname: Deecke
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D005702:Galantamine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010865:Pilot Projects
chemical_list: D005702:Galantamine